Arbor Biotechnologies

Arbor is a private biotech company, so investment decisions are made by its board and management, led by CEO Devyn Smith. Key board members include Paul Meister (Chairman), Keith Crandell (Arch Venture Partners), and Mark Angelino (Third Rock Ventures) who represent major investors. The company has raised venture capital from Arch, Third Rock, and other top life sciences investors (per the firm's website).

Arbor generates its own pipeline through internal discovery of novel CRISPR systems — it does not primarily license editors from others. The company has built a portfolio of proprietary DNA editors covering over 90% of the human genome, which it then uses to develop targeted therapies for rare genetic diseases (per the firm).

Neither. Arbor Biotechnologies is a private gene editing therapeutics company, not a family office or venture firm. It is funded by venture capital from institutional investors like Arch Venture Partners and Third Rock Ventures, and it operates as a drug developer with its own pipeline of clinical-stage candidates.

Arbor does not make investments; it raises capital from institutional investors to fund its internal R&D. The company has executed partnerships and licensing deals with larger pharma companies like Vertex and Chiesi, which provide non-dilutive funding and collaboration support.

Arbor is not an investor; it is a company that itself progresses from discovery through clinical development. Its most advanced candidate, ABO-101, reached IND clearance and regulatory approvals in 2025 — representing a late-stage development milestone for a biotech.

There is no publicly disclosed philanthropic arm at Arbor. The company operates as a for-profit biotech focused on developing gene editing therapies. Its founders include academics affiliated with the Broad Institute and Harvard, but those institutional ties are separate from Arbor's commercial operations.